Mycophenolic acid pharmacogenomics in kidney transplantation

Abstract

Mycophenolic acid (MPA) is a potent antiproliferative drug prescribed to prevent acute rejection in kidney transplantation. MPA reversibly inhibits the enzymes involved in the synthesis of guanosine nucleotides, thus preventing DNA replication of immune cells. Consequently, the repression of both cell and humoral immunity induces renal allograft tolerance. MPA is an effective and safe immunosuppressive drug, but some patients show variability in drug concentration, acute rejection, graft dysfunction, or MPA-related adverse events. Although the pharmacogenomics of immunosuppressive drugs has been widely investigated, MPA has been explored to a lesser extent. This review of MPA pharmacogenomic studies, included pharmacokinetics, adverse events, and main clinical outcomes of MPA treatment in kidney transplantation. Associations of variants in genes encoding MPA metabolizing enzymes, transporters, and targets with drug efficacy and safety are described. Most pharmacogenetic studies have focused on small sample sizes and few simultaneously analyzed genetic variants. Some studies reported significant associations of pharmacokinetics- and pharmacodynamics-related genes with MPA exposure, acute rejection, graft dysfunction, hematological events, and gastrointestinal complications. However, even large cohorts did not replicate the findings, possibly due to divergent study design, immunosuppressive scheme, follow-up time, and other factors. Finally, the heterogeneity of aspects between studies limit conclusions on pharmacogenetic biomarkers of MPA in kidney transplantation.

Keywords

Immunosuppressive therapy / mycophenolic acid / kidney transplantation / pharmacogenomics / pharmacodynamics / pharmacokinetics

References

[1] BentataY.Mycophenolates: the latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them?.Artif Organs2020;44:561-76

[2] GuoM,YangHW,TanRY.Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation..Curr Drug Metab2018;19:1199-205

[3] StaatzCE.Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update..Arch Toxicol2014;88:1351-89

[4] da SilvaMB,TerraFF.Old game, new players: Linking classical theories to new trends in transplant immunology..World J Transplant2017;7:1-25 PMCID:PMC5324024

[5] CooperM,BuddeK,SollingerH.Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing..Transplant Rev (Orlando)2012;26:233-40

[6] FujiyamaN,KatoS,IsobeM.Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil..Drug Metab Dispos2010;38:2210-7

[7] BurgM,WieserC,FischerW.Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients..Transplant Proc2009;41:4159-64

[8] van GelderT.Mycophenolate revisited..Transpl Int2015;28:508-15

[9] BernardO.The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants..Drug Metab Dispos2004;32:775-8

[10] Meier-KriescheHU,KoreckaM.Pharmacokinetics of mycophenolic acid in renal insufficiency..Ther Drug Monit2000;22:27-30

[11] ShipkovaM,OellerichM.Acyl glucuronide drug metabolites: toxicological and analytical implications..Ther Drug Monit2003;25:1-16

[12] PicardN,PrémaudA.Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5..Ther Drug Monit2004;26:600-8

[13] MichelonH,DurrbachA,VerstuyftC.SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients..Pharmacogenomics2010;11:1703-13

[14] PicardN,WoillardJB,Le MeurY.The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics..Clin Pharmacol Ther2010;87:100-8 PMCID:PMC2884029

[15] WestleyIS,MorrisRG,SallustioBC.Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine..Drug Metab Dispos2006;34:261-6

[16] KobayashiM,KobayashiM,TakahashiY.Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats..J Pharmacol Exp Ther2004;309:1029-35

[17] JetterA.Drugs and hepatic transporters: a review..Pharmacol Res2020;154:104234

[18] WangJ,ShawLM.The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice..Transpl Immunol2008;19:192-6

[19] PatelCG,AkhlaghiF.Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus..Xenobiotica2013;43:229-35 PMCID:PMC4116557

[20] WangD,JinQ,GeG.Human carboxylesterases: a comprehensive review..Acta Pharm Sin B2018;8:699-712 PMCID:PMC6146386

[21] FujiyamaN,SatohS,KagayaH.Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients..Xenobiotica2009;39:407-14

[22] CiliãoHL,SouzaMF,DelfinoVDA.Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil..Mutat Res Genet Toxicol Environ Mutagen2018;836:97-102

[23] SatohS,MurakamiM,LiZ.Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients..Transplantation2006;82:486-93

[24] GenvigirFDV,FelipeCR,Medina-PestanaJO.CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy..Pharmacogenomics2020;21:7-21

[25] GrinyóJ,NashanB,EkbergH.Association of four DNA polymorphisms with acute rejection after kidney transplantation..Transpl Int2008;21:879-91

[26] GrendaR,CiechanowiczA,KalicińskiP.Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients - a retrospective study..Ann Transplant2009;14:18-24

[27] VarnellCD,KirbyCL,WarshawBL.Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs..Pediatr Transplant2017;21:e13033 PMCID:PMC5905326

[28] JacobsonPA,OettingWS,GuanW.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation..Transplantation2011;91:309-16 PMCID:PMC3711617

[29] WoillardJB,ThierryA,MarquetP.Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients..Pharmacogenet Genomics2014;24:256-62 PMCID:PMC5127810

[30] GenvigirFDV,FelipeCR,OliveiraN.Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in brazilian kidney transplant recipients..Pharmacotherapy2017;37:535-45

[31] BernardO,JournaultK,GuillemetteC.Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid..Drug Metab Dispos2006;34:1539-45

[32] MeechR,McKinnonRA,HainesAZ.The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms..Physiol Rev2019;99:1153-222

[33] InoueK,SatohS,SaitoM.Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients..Ther Drug Monit2007;29:299-304

[34] WoillardJB,PicardN,DrouetM.Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele..Br J Clin Pharmacol2010;69:675-83 PMCID:PMC2883760

[35] XieXC,WangHY,LiuJ.Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients..Acta Pharmacol Sin2015;36:644-50 PMCID:PMC4422949

[36] KagayaH,MiuraM,SaitoM.Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients..Eur J Clin Pharmacol2007;63:279-88

[37] GengF,DaoYJ,DingJJ.The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals..Clin Chim Acta2012;413:683-90

[38] LiLQ,LiCJ,ChenY.Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients..Pharmacogenomics2018;19:1323-34

[39] van SchaikRH,de FijterJW,SchmidtJ.UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients..Clin Pharmacol Ther2009;86:319-27

[40] ZhaoW,DeschênesG,BrochardK.Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients..J Clin Pharmacol2010;50:1280-91

[41] VuD,YangJ,ShahT.Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid..Transpl Immunol2013;29:155-61

[42] BetônicoGN,Goloni-BertolloEM,GuillemetteC.Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients..Transplant Proc2008;40:708-10

[43] PrausaSE,MaseckD,LiuC.UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients..Clin Pharmacol Ther2009;85:495-500

[44] GirardH,BernardO,VilleneuveL.Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver..Pharmacogenetics2004;14:501-15

[45] KuypersDR,NaesensM,HalewijckE.Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients..Clin Ther2008;30:673-83

[46] Sánchez-FructuosoAI,CalvoN,Pérez-FloresI.The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients..Transplant Proc2009;41:2313-6

[47] KuypersDR,VermeireS.The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients..Clin Pharmacol Ther2005;78:351-61

[48] BaldelliS,PericoN,CortinovisM.C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation..Pharmacogenomics2007;8:1127-41

[49] KiangTKL,ShapiroRJ,CollierAC.Regression and genomic analyses on the association between dose-normalized mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients..Clin Drug Investig2018;38:1011-22

[50] YuZC,WangXH,XuD.Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients..Acta Pharmacol Sin2017;38:1566-79 PMCID:PMC5672070

[51] PazikJ,DąbrowskiM,SitarekE.Association of UDP-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function..Ann Transplant2011;16:69-73

[52] PazikJ,LewandowskiZ,PodgórskaM.Recipient uridine 5’-diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate..Transplant Proc2014;46:2678-82

[53] DjebliN,RérolleJP,MarquetP.Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients..Pharmacogenet Genomics2007;17:321-30

[54] van AgterenM,van SchaikRH,HartmannA.AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism..Ther Drug Monit2008;30:439-44

[55] CattaneoD,GaspariF,RemuzziG.Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation..Kidney Int2002;62:1060-7

[56] DuguayY,SkorpenF.A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity..Clin Pharmacol Ther2004;75:223-33

[57] YooEC,TodorovaEK.Developmental changes of MPA exposure in children..Pediatr Nephrol2016;31:975-82

[58] BruhnO.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance..Expert Opin Drug Metab Toxicol2014;10:1337-54

[59] BouamarR,van SchaikRH,van der HeidenIP.Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients..Pharmacogenet Genomics2012;22:399-407

[60] TreiberA,HäuslerS.Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil..Drug Metab Dispos2007;35:1400-7

[61] StaatzCE,TettSE.Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I..Clin Pharmacokinet2010;49:141-75

[62] NaesensM,VerbekeK.Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients..Transplantation2006;82:1074-84

[63] LloberasN,CruzadoJM,OppenheimerF.Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the pharmacogenomic substudy within the symphony study..Nephrol Dial Transplant2011;26:3784-93

[64] BožinaN,Nađ-ŠkegroS,BožinaT.Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients’ and donors’ ABCC2 gene variants, and their interactions..Eur J Clin Pharmacol2017;73:1129-40

[65] MiuraM,InoueK,SaitoM.Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients..Eur J Clin Pharmacol2007;63:1161-9

[66] ColomH,AndreuF,TorrasJ.Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients..Kidney Int2014;85:1434-43

[67] LiTT,XuJY.Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver..World J Clin Cases2019;7:3915-33 PMCID:PMC6906560

[68] SongW,TaoL,ChenL.Solute carrier transporters: the metabolic gatekeepers of immune cells..Acta Pharm Sin B2020;10:61-78 PMCID:PMC6977534

[69] KalliokoskiA.Impact of OATP transporters on pharmacokinetics..Br J Pharmacol2009;158:693-705 PMCID:PMC2765590

[70] WuTY,PelleymounterLL,EckloffBW.Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics..Br J Pharmacol2010;161:1584-98 PMCID:PMC3010569

[71] WangJ,ZeeviA,GirnitaDM.IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients..Clin Pharmacol Ther2008;83:711-7

[72] GensburgerO,PicardN,RousseauA.Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil..Pharmacogenet Genomics2010;20:537-43 PMCID:PMC3235084

[73] ShahS,DöhlerB,YaqoobMM.Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome..Transplantation2012;94:486-91

[74] KagayaH,SaitoM,SatohS.Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation..Basic Clin Pharmacol Toxicol2010;107:631-6

[75] PazikJ,NowackaCieciura E,PodgórskaM.Malnutrition risk in kidney recipients treated with mycophenolate mofetil is associated with IMPDH1 rs2278294 polymorphism..Transplant Proc2018;50:1794-7

[76] WangJ,WebberS,AddonizioL.A novel variant L263F in human inosine 5’-monophosphate dehydrogenase 2 is associated with diminished enzyme activity..Pharmacogenet Genomics2007;17:283-90

[77] MohamedMF,LangaeeTY.Interpopulation variation frequency of human inosine 5’-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms..Genet Test2008;12:513-6

[78] SombogaardF,MathotRA,van der WerfM.Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism..Pharmacogenet Genomics2009;19:626-34

[79] WinnickiW,Sunder-PlassmannG,WinterB.An inosine 5’-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid..Pharmacogenomics J2010;10:70-6

[80] PazikJ,PodgórskaM,SitarekE.Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism..Transplant Proc2011;43:2943-5

[81] McDonaghEM,GartenY,KleinTE.From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource..Biomark Med2011;5:795-806 PMCID:PMC3339046

[82] Whirl-CarrilloM,HebertJM,SangkuhlK.Pharmacogenomics knowledge for personalized medicine..Clin Pharmacol Ther2012;92:414-7 PMCID:PMC3660037

[83] HanN,KimIW,KimYS.Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients..Eur J Clin Pharmacol2014;70:1211-9

[84] ZhangWX,JinZ,WangX.Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients..Xenobiotica2008;38:1422-36

[85] OliveraG,HerreroMJ,GargalloP.Pharmacogenetics implementation in the clinics: information and guidelines for germline variants..CDR2019;

[86] MessinaE,GiacomelloA.Guanine nucleotide depletion induces differentiation and aberrant neurite outgrowth in human dopaminergic neuroblastoma lines: a model for basal ganglia dysfunction in Lesch-Nyhan disease..Neurosci Lett2005;375:97-100

[87] ZhangJ,ZhuZ,KangJ.Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients..Front Pharmacol2018;9:908 PMCID:PMC6099482

[88] MarquetP.Counterpoint: is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?.Clin Chem2010;56:736-9

[89] MetzDK,KausmanJY,CranswickN.Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention..Transplantation2019;103:2012-30 PMCID:PMC6756255

[90] PicardN,MarquetP,WallemacqP.Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs..Ther Drug Monit.2016;38 Suppl 1:S57-69